 Aimmune Therapeutics, Inc. Nasdaq: AIMT, a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 Allergy to Peanuts ImPacting Emotions And Life-1, a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published in Allergy, one of the official journals of European Academy of Allergy and Clinical Immunology EAACI. The study, published in two parts Part A and Part B, highlights the substantial impact peanut allergy has on every aspect of allergic individuals and their caregivers lives, including the uncertainty they feel around how to manage frightening and debilitating reactions and concerns about the feasibility of ongoing avoidance. 